• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表达可溶性脊髓灰质炎病毒受体的重组溶瘤腺病毒引发长期抗肿瘤免疫监视。

Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance.

作者信息

Zhang Hailin, Zhang Yonghui, Dong Jie, Li Binghua, Xu Chun, Wei Min, Wu Junhua, Wei Jiwu

机构信息

Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, 22 Hankou Road, Nanjing, Jiangsu 210093, China.

National Institute of Healthcare Data Science at Nanjing University, Nanjing University, 22 Hankou Road, Nanjing, Jiangsu 210093, China.

出版信息

Mol Ther Oncolytics. 2020 Nov 17;20:12-22. doi: 10.1016/j.omto.2020.11.001. eCollection 2021 Mar 26.

DOI:10.1016/j.omto.2020.11.001
PMID:33575467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7851489/
Abstract

Oncolytic virotherapy (OVT) has been suggested to be effective. However, the suppressive effects of checkpoints and insufficient costimulatory signals limit OVT-induced antitumor immune responses. In this study, we constructed a replicative adenovirus, Ad5sPVR, that expresses the soluble extracellular domain of poliovirus receptor (sPVR). We showed that sPVR can bind to both T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) and CD226, and the binding affinity of sPVR to TIGIT is stronger than that of PVR to CD226. In the H22 hepatocellular carcinoma (HCC) ascites model, Ad5sPVR treatment increased the infiltration of CD8 T cells and the release of interferon (IFN)-γ, exhibiting an antitumor effect with long-term tumor-specific immune surveillance. In line with this, Ad5sPVR also effectively improved antitumor outcomes in solid tumors. In conclusion, while Ad5sPVR plays a role in oncolysis and transforms cold tumors into hot tumors, sPVR expressed by Ad5sPVR can block the PVR/TIGIT checkpoint and activate CD226, thereby greatly improving the efficacy of OVT. This study provides a new way to develop potential oncolytic viral drugs.

摘要

溶瘤病毒疗法(OVT)已被证明是有效的。然而,检查点的抑制作用和共刺激信号不足限制了OVT诱导的抗肿瘤免疫反应。在本研究中,我们构建了一种复制型腺病毒Ad5sPVR,它表达脊髓灰质炎病毒受体的可溶性细胞外结构域(sPVR)。我们发现sPVR能同时结合T细胞免疫球蛋白和基于免疫受体酪氨酸的抑制基序结构域(TIGIT)以及CD226,且sPVR与TIGIT的结合亲和力强于PVR与CD226的结合亲和力。在H22肝癌(HCC)腹水模型中,Ad5sPVR治疗增加了CD8 T细胞浸润和干扰素(IFN)-γ释放,展现出具有长期肿瘤特异性免疫监视的抗肿瘤作用。与此一致,Ad5sPVR在实体瘤中也有效改善了抗肿瘤效果。总之,虽然Ad5sPVR在溶瘤中发挥作用并将冷肿瘤转变为热肿瘤,但Ad5sPVR表达的sPVR可阻断PVR/TIGIT检查点并激活CD226,从而大大提高OVT的疗效。本研究为开发潜在的溶瘤病毒药物提供了一种新方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9e6/7851489/7b478b03ab26/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9e6/7851489/e83ed4e48c96/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9e6/7851489/bbfb83a8f2ca/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9e6/7851489/30b383372e52/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9e6/7851489/b7236b64bd7a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9e6/7851489/11a28489f1e8/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9e6/7851489/7b478b03ab26/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9e6/7851489/e83ed4e48c96/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9e6/7851489/bbfb83a8f2ca/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9e6/7851489/30b383372e52/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9e6/7851489/b7236b64bd7a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9e6/7851489/11a28489f1e8/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9e6/7851489/7b478b03ab26/gr5.jpg

相似文献

1
Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance.表达可溶性脊髓灰质炎病毒受体的重组溶瘤腺病毒引发长期抗肿瘤免疫监视。
Mol Ther Oncolytics. 2020 Nov 17;20:12-22. doi: 10.1016/j.omto.2020.11.001. eCollection 2021 Mar 26.
2
Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8 T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma.表达融合蛋白 PD1PVR 的重组腺病毒增强了 CD8 T 细胞介导的抗肿瘤疗效,并具有长期的肿瘤特异性免疫监视作用,可用于治疗肝细胞癌。
Cell Oncol (Dordr). 2021 Dec;44(6):1243-1255. doi: 10.1007/s13402-021-00633-w. Epub 2021 Sep 7.
3
An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.一种工程化的溶瘤痘苗病毒,编码针对 TIGIT 的单链可变片段,可诱导有效的抗肿瘤免疫,并与 PD-1 或 LAG-3 阻断协同作用。
J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-002843.
4
Perturbed CD8 T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals.干扰 CD8 T 细胞 TIGIT/CD226/PVR 轴,尽管在 HIV 感染者中早期启动了抗逆转录病毒治疗。
Sci Rep. 2017 Jan 13;7:40354. doi: 10.1038/srep40354.
5
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.TIGIT-CD226-PVR 轴:推进免疫检查点阻断治疗癌症免疫疗法。
J Immunother Cancer. 2022 Apr;10(4). doi: 10.1136/jitc-2022-004711.
6
CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT.CD155 突变(Ala67Thr)增加了与抑制性免疫受体 TIGIT 的结合亲和力和信号转导。
Cancer Sci. 2022 Nov;113(11):4001-4004. doi: 10.1111/cas.15526. Epub 2022 Aug 30.
7
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.TIGIT/CD226轴调节抗肿瘤免疫。
Pharmaceuticals (Basel). 2021 Feb 28;14(3):200. doi: 10.3390/ph14030200.
8
Higher TIGITCD226 γδ T cells in Patients with Acute Myeloid Leukemia.急性髓系白血病患者中高表达 TIGITCD226 γδ T 细胞。
Immunol Invest. 2022 Jan;51(1):40-50. doi: 10.1080/08820139.2020.1806868. Epub 2020 Aug 20.
9
Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8 T Cells in HCC.表达可溶性融合蛋白 PD-1/CD137L 的重组腺病毒在 HCC 中颠覆了 CD8 T 细胞的抑制作用。
Mol Ther. 2019 Nov 6;27(11):1906-1918. doi: 10.1016/j.ymthe.2019.07.019. Epub 2019 Aug 5.
10
Competitive binding of CD226/TIGIT with poliovirus receptor regulates macrophage polarization and is involved in vascularized skin graft rejection.CD226/TIGIT 与脊髓灰质炎病毒受体的竞争性结合调节巨噬细胞极化,并参与血管化皮肤移植物排斥反应。
Am J Transplant. 2023 Jul;23(7):920-934. doi: 10.1016/j.ajt.2023.04.007. Epub 2023 Apr 11.

引用本文的文献

1
Serotonin (5-Hydroxytryptamine): Metabolism, Signaling, Biological Functions, Diseases, and Emerging Therapeutic Opportunities.血清素(5-羟色胺):代谢、信号传导、生物学功能、疾病及新兴治疗机遇
MedComm (2020). 2025 Sep 9;6(9):e70383. doi: 10.1002/mco2.70383. eCollection 2025 Sep.
2
Oncolytic vaccinia virus expressing non-secreted decoy-resistant IL-18 mutein elicits potent antitumor effects with enhanced safety.表达非分泌型抗诱饵IL-18突变体的溶瘤痘苗病毒具有增强的安全性,并能引发强大的抗肿瘤作用。
Mol Ther Oncol. 2025 Jul 21;33(3):201022. doi: 10.1016/j.omton.2025.201022. eCollection 2025 Sep 18.
3
Potential Roles of Serum Exosomal CD155 and its Impact on NK Cell Immunosuppression in Hepatocellular Carcinoma.

本文引用的文献

1
TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling.TNFa 和 IL2 编码溶瘤腺病毒激活病原体和危险相关免疫信号。
Cells. 2020 Mar 26;9(4):798. doi: 10.3390/cells9040798.
2
NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer.自然杀伤细胞增强溶瘤腺病毒对卵巢癌的细胞毒性。
Mol Ther Oncolytics. 2020 Feb 15;16:289-301. doi: 10.1016/j.omto.2020.02.001. eCollection 2020 Mar 27.
3
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
血清外泌体CD155在肝细胞癌中的潜在作用及其对自然杀伤细胞免疫抑制的影响
Balkan Med J. 2025 May 5;42(3):242-253. doi: 10.4274/balkanmedj.galenos.2025.2025-1-129.
4
Formin protein FMNL1 is a biomarker for tumor-infiltrating immune cells and associated with well immunotherapeutic response.成束蛋白FMNL1是肿瘤浸润免疫细胞的生物标志物,与良好的免疫治疗反应相关。
J Cancer. 2023 Sep 11;14(16):2978-2989. doi: 10.7150/jca.86965. eCollection 2023.
5
The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity.单纯的脊髓灰质炎病毒受体 IgV 结构域具有免疫抑制作用,并以相当的亲和力与其受体结合。
Sci Rep. 2023 Mar 21;13(1):4609. doi: 10.1038/s41598-023-30999-w.
6
CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy.携 CXCL10 的溶瘤腺病毒促进肿瘤浸润 T 细胞趋化,以增强抗 PD-1 治疗。
Oncoimmunology. 2022 Aug 31;11(1):2118210. doi: 10.1080/2162402X.2022.2118210. eCollection 2022.
7
Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy.CD155/TIGIT在消化系统癌症中的作用:免疫治疗有前景的癌症靶点
Front Oncol. 2022 Mar 30;12:844260. doi: 10.3389/fonc.2022.844260. eCollection 2022.
8
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.工程策略增强溶瘤病毒在癌症免疫治疗中的作用。
Signal Transduct Target Ther. 2022 Apr 6;7(1):117. doi: 10.1038/s41392-022-00951-x.
溶瘤腺病毒武装双特异性 T 细胞结合分子、细胞因子和检查点抑制剂使 CAR T 细胞能够控制异质性肿瘤的生长。
Mol Ther. 2020 May 6;28(5):1251-1262. doi: 10.1016/j.ymthe.2020.02.016. Epub 2020 Feb 24.
4
Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.溶瘤单纯疱疹病毒 1 编码的 PD-1 阻断 scFv 瘤内递呈促进抗肿瘤免疫,并与 TIGIT 阻断协同作用。
Cancer Immunol Res. 2020 May;8(5):632-647. doi: 10.1158/2326-6066.CIR-19-0628. Epub 2020 Mar 3.
5
Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.端粒酶特异性溶瘤腺病毒的免疫调节作用与抗 PD1 抗体协同增强抗肿瘤疗效。
Mol Ther. 2020 Mar 4;28(3):794-804. doi: 10.1016/j.ymthe.2020.01.003. Epub 2020 Jan 10.
6
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer.靶向TIGIT-PVR免疫检查点轴作为乳腺癌的新型治疗选择。
Oncoimmunology. 2019 Oct 12;8(12):e1674605. doi: 10.1080/2162402X.2019.1674605. eCollection 2019.
7
Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8 T Cells in HCC.表达可溶性融合蛋白 PD-1/CD137L 的重组腺病毒在 HCC 中颠覆了 CD8 T 细胞的抑制作用。
Mol Ther. 2019 Nov 6;27(11):1906-1918. doi: 10.1016/j.ymthe.2019.07.019. Epub 2019 Aug 5.
8
Optimizing oncolytic virotherapy in cancer treatment.优化溶瘤病毒治疗癌症。
Nat Rev Drug Discov. 2019 Sep;18(9):689-706. doi: 10.1038/s41573-019-0029-0. Epub 2019 Jul 10.
9
Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway.伊维菌素通过 EGFR/ERK/Akt/NF-κB 通路逆转癌细胞的耐药性。
J Exp Clin Cancer Res. 2019 Jun 18;38(1):265. doi: 10.1186/s13046-019-1251-7.
10
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.免疫检查点抑制剂的不良反应:流行病学、管理和监测。
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580. doi: 10.1038/s41571-019-0218-0.